{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:09Z","timestamp":1788300789162,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128887","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:16:43Z","timestamp":1782501403000},"page":"128887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study"],"prefix":"10.1016","volume":"89","author":[{"given":"Naoki","family":"Tani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128887_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0010","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128887_bb0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S2213-2600(23)00306-5","article-title":"Effectiveness of BNT162b2 BA. 4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case\u2013control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Nick","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B. 1.1. 7 and B. 1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0030","author":"Pfizer-BioNTech"},{"key":"10.1016\/j.vaccine.2026.128887_bb0035","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2022.02.025","article-title":"Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine","volume":"40","author":"Tani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128887_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac493","article-title":"Correlation of postvaccination fever with specific antibody response to severe acute respiratory syndrome coronavirus 2 BNT162b2 booster and no significant influence of antipyretic medication","volume":"9","author":"Tani","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128887_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.15585\/mmwr.mm7107e1","article-title":"Safety monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128887_bb0050","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12913-025-12482-6","article-title":"Hesitancy towards COVID-19 booster vaccine among healthcare workers in Bangladesh","volume":"25","author":"Shoshi","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2026.128887_bb0055","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.vaccine.2022.04.046","article-title":"Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination","volume":"40","author":"Chrissian","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128887_bb0060","doi-asserted-by":"crossref","unstructured":"Bando T, Ikematsu H, Hamada K, Negami M, Fujii H, Doniwa K et al. Promoting COVID-19 vaccination: results of a 2024 Japanese survey of outpatient intention to vaccinate. J Infect Chemother;32:102911. Doi: https:\/\/doi.org\/10.1016\/J.JIAC.2026.102911.","DOI":"10.1016\/j.jiac.2026.102911"},{"key":"10.1016\/j.vaccine.2026.128887_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100489","article-title":"Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations","volume":"18","author":"Tani","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128887_bb0070","doi-asserted-by":"crossref","first-page":"eabj9256","DOI":"10.1126\/sciimmunol.abj9256","article-title":"COVID-19 vaccine side effects: the positives about feeling bad","volume":"6","author":"Sprent","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.128887_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife\u2019s edge: balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0080","article-title":"Fever after vaccination against SARS-CoV-2 with mRNA-based vaccine associated with higher antibody levels during 6 months follow-up","volume":"10","author":"Kanizsai","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128887_bb0085","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.vaccine.2022.02.052","article-title":"Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128887_bb0090","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1038\/s41598-024-57931-0","article-title":"Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-na\u00efve adults receiving the first four mRNA COVID-19 vaccine doses","volume":"14","author":"Matsuura","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128887_bb0095","doi-asserted-by":"crossref","unstructured":"Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020;58:10\u20131128.","DOI":"10.1128\/JCM.02005-20"},{"key":"10.1016\/j.vaccine.2026.128887_bb0100","doi-asserted-by":"crossref","first-page":"22848","DOI":"10.1038\/s41598-021-01930-y","article-title":"Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals","volume":"11","author":"Maeda","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128887_bb0105","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1016\/j.vaccine.2023.10.035","article-title":"Distinct features of SARS-CoV-2 humoral immunity against omicron breakthrough infection","volume":"41","author":"Goto","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128887_bb0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128887_bb0115","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/infdis\/jiad472","article-title":"Durability of cross-neutralizing antibodies 5.5 months after bivalent coronavirus disease 2019 vaccine booster","volume":"229","author":"R\u00f6ssler","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128887_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102842","article-title":"Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination","volume":"31","author":"Goto","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2026.128887_bb0125","article-title":"Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups","volume":"59","author":"Madhusudhanan","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2026.128887_bb0130","series-title":"Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"Guidance for Industry","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128887_bb0135","article-title":"Safety and immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 years old: a phase 2\/3 trial","volume":"12","author":"Gayed","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128887_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126869","article-title":"A phase 2\/3 trial to investigate the safety and immunogenicity of monovalent omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults \u226518 years old","volume":"52","author":"Diya","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128887_bb0145","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science (1979)"},{"key":"10.1016\/j.vaccine.2026.128887_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.05.010","article-title":"SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors","volume":"89","author":"Terpos","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0155","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128887_bb0160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128887_bb0165","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1473-3099(23)00181-0","article-title":"SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster","volume":"23","author":"Wang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128887_bb0170","series-title":"COMIRNATY\u00ae [COVID-19 mRNA vaccine] product monograph","author":"BioNTech Manufacturing GmbH","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128887_bb0175","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Sol\u00eds Arce","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0180","doi-asserted-by":"crossref","first-page":"e210804","DOI":"10.1001\/jamahealthforum.2021.0804","article-title":"Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group","volume":"2","author":"Rief","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.vaccine.2026.128887_bb0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s12967-025-06837-0","article-title":"Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters","volume":"23","author":"Pradenas","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2026.128887_bb0190","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1093\/cid\/ciab004","article-title":"The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers","volume":"73","author":"Lumley","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:19:53Z","timestamp":1788297593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26006961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S0264410X26006961"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128887","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128887"}}